
Clinically significant adverse reactions to a supra-therapeutic dose could include cardiovascular, neurologic, psychiatric and gastrointestinal reactions. Customers who have this lot in their possession are instructed to cease using the product and return it to their pharmacy/distributor.
XStream Systems, endorses material screening of medications within the supply chain from manufacturer to dispenser to significantly reduce issues with product quality, adulterated and counterfeit medications. By using solutions like XStream’s XT250, a user can verify and authenticate medications inside their sealed, unit-of-sale container without opening or destroying the product.
Read the MedWatch safety summary, including a link to the firm's Press Release, at:
www.fda.gov.
No comments:
Post a Comment